3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
6
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Thoracic
1
Conditions
Ovarian Neoplasms
23
Peritoneal Neoplasms
18
Colorectal Neoplasms
10
Stomach Neoplasms
9
Fallopian Tube Neoplasms
8
Endometrial Neoplasms
8
Colonic Neoplasms
7
Neoplasm Metastasis
6
Carcinoma, Ovarian Epithelial
6
Rectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Renal Cell
4
Appendiceal Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Pseudomyxoma Peritonei
2
Prostatic Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Interventions
pembrolizumab
17
Carboplatin
10
Paclitaxel
7
Trastuzumab
5
Nivolumab
5
Gemcitabine
5
Early Intervention, Educational
5
Cyclophosphamide
5
Cisplatin
5
fludarabine
4
cemiplimab
4
Psychiatric Rehabilitation
4
Fluorouracil
4
Docetaxel
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
belinostat
3
Radiotherapy
3
Polymerase Chain Reaction
3
Methods
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Fluorodeoxyglucose F18
3
Biopsy
3
zimberelimab
2
ulixertinib
2
pertuzumab
2
palbociclib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Oxaliplatin
×
Gynecologic
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled